Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.23.1
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2022
Nov. 30, 2019
Jan. 31, 2018
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized           $ 2,954 $ 5,467  
Deferred revenue           3,245   $ 4,330
Global Blood Therapeutics                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue           $ 3,245   $ 4,330
Global Blood Therapeutics | Collaboration Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Initial period of research term 3 years              
Additional extension period for research term upon mutual agreement 1 year              
Upfront payment receivable $ 20,000              
Research agreement expiration month and year     2023-12          
Additional extension period for research term     1 year     1 year    
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000              
Agreement termination, prior written notice if notice delivered during the research term 90 days              
Research agreement additional consideration           $ 7,100    
Deferred revenue, short-term           3,200    
Estimated transaction price           56,400    
Agreement termination, prior written notice if notice delivered during the research term 9 months              
Total transaction price $ 60,000              
Upfront non-refundable and non-creditable payment 20,000              
Reimbursable costs $ 40,000              
Revenue recognized           3,000 5,100  
Global Blood Therapeutics | Collaboration Agreement | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Period of extension of initial research term 2 years              
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000              
Incyte                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue, short-term           0    
Revenue recognized           0 $ 400  
Incyte | Stock Purchase Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Aggregate purchase price         $ 10,000      
Shares issued         79,302      
Share price (in dollars per share)         $ 126.10      
Premium to volume-weighted sale price of shares (as a percent)         30.00%      
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares         15 days      
Incyte | Collaboration Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total transaction price   $ 12,300   $ 12,800   12,800    
Upfront non-refundable and non-creditable payment           2,500    
Up-front consideration         $ 10,000      
Up-front consideration, cash         2,500      
Up-front consideration, pre-paid research funding         $ 7,500      
Prepaid research amount           7,500    
Premium paid on equity investment           2,300    
Collaboration agreement additional consideration incurred           $ 500